BiotechTube

DCCR + Placebo for DCCR

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

May 9, 2018 → May 1, 2020

NCT ID
NCT03440814

About DCCR + Placebo for DCCR

DCCR + Placebo for DCCR is a phase 3 stage product being developed by Soleno Therapeutics for Prader-Willi Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03440814. Target conditions include Prader-Willi Syndrome.

What happened to similar drugs?

0 of 8 similar drugs in Prader-Willi Syndrome were approved

Approved (0) Terminated (1) Active (7)
🔄somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3
🔄CarbetocinAcadia PharmaceuticalsPhase 3
🔄Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
🔄DCCRSoleno TherapeuticsPhase 3
🔄DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
🔄PitolisantHarmony BiosciencesPhase 3
🔄Pitolisant tabletHarmony BiosciencesPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03440814Phase 3Completed

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors
ProductCompanyStageHype Score
Octreotide + PlaceboNovartisPre-clinical
18
Norditropin SimpleXxNovo NordiskPre-clinical
26
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3
40
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 2
32
SetmelanotideRhythm PharmaceuticalsPhase 2
36
RGH-706 + PlaceboRichter GedeonPhase 2
32
CarbetocinAcadia PharmaceuticalsPhase 3
44
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
41
DCCRSoleno TherapeuticsPhase 3
38
DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
34
PitolisantHarmony BiosciencesPhase 3
41
Pitolisant tabletHarmony BiosciencesPhase 3
41
Pitolisant oral tablets + Placebo oral tabletHarmony BiosciencesPhase 2
33
DCCRSoleno TherapeuticsPhase 3
26
VYKAT XRSoleno TherapeuticsPre-clinical
27
NNZ-2591Neuren PharmaceuticalsPhase 2
21
BMB-101 + PlaceboBright Minds BiosciencesPhase 2
36
ARD-101Aardvark TherapeuticsPhase 2
25